5-Aza-2'-deoxycytidine as a differentiation inducer in acute myeloid leukaemias and myelodysplastic syndromes of the elderly
Pinto, A.; Zagonel, V.; Attadia, V.; Bullian, P.L.; Gattei, V.; Carbone, A.; Monfardini, S.; Colombatti, A.
Bone Marrow Transplantation 4(Suppl): 28-32
1989
ISSN/ISBN: 0268-3369 PMID: 2483349 Document Number: 337655
Document emailed within 1 workday
Related Documents
Januszewicz, E.H.; Firkin, F.C. 1988: Differentiation in acute myeloid leukemia and myelodysplastic disorders. Is differentiation-induction therapy possible? Australian and New Zealand Journal of Medicine 18(5): 705-711Li, L.-j.; Fu, R.; Wang, H.-q.; Yue, L.-z.; Liu, H.; Wang, J.; Wang, H.-l.; Ruan, E.-b.; Qu, W.; Liang, Y.; Wang, G.-j.; Wang, X.-m.; Liu, H.; Song, J.; Wu, Y.-h.; Xing, L.-m.; Guan, J.; Shao, Z.-h. 2010: Expression of differentiation antigens on bone marrow myeloid cells of the patients with myelodysplastic syndromes and its clinical significances Zhonghua Yi Xue Za Zhi 90(10): 672-677
Farhi, D.C. 1995: Myelodysplastic syndromes and acute myeloid leukemia. Diagnostic criteria and pitfalls Pathology Annual 30: 29-57
Xu, K.; Wang, L.; Hao, Y.; Shao, Z.; Meng, Q.; Li, K.; Chao, H.; Tang, K.; Wang, L. 1999: Evi-1 and MDS1-Evi-1 genes in pathogenesis of myelodysplastic syndromes and post-MDS acute myeloid leukemia Chinese Medical Journal 112(12): 1112-1118
Steensma, D.P. 2007: The spectrum of molecular aberrations in myelodysplastic syndromes: in the shadow of acute myeloid leukemia Haematologica 92(6): 723-727
Zagonel, V.; Lo Re, G.; Marotta, G.; Babare, R.; Sardeo, G.; Gattei, V.; De Angelis, V.; Monfardini, S.; Pinto, A. 1993: 5-Aza-2'-deoxycytidine (Decitabine) induces trilineage response in unfavourable myelodysplastic syndromes Leukemia 7(Suppl 1): 30-35
Lai, J.L.; Preudhomme, C.; Zandecki, M.; Flactif, M.; Vanrumbeke, M.; Lepelley, P.; Wattel, E.; Fenaux, P. 1995: Myelodysplastic syndromes and acute myeloid leukemia with 17p deletion. An entity characterized by specific dysgranulopoïesis and a high incidence of P53 mutations Leukemia 9(3): 370-381
Bernell, P.; Kimby, E.; Hast, R. 1994: Recombinant human granulocyte-macrophage colony-stimulating factor in combination with standard induction chemotherapy in acute myeloid leukemia evolving from myelodysplastic syndromes: a pilot study Leukemia 8(10): 1631-1639
Mugneret, F.; Callier, P.; Favre-Audry, B. 2003: Chromosomal abnormalities in acute myeloid leukaemias Pathologie-Biologie 51(6): 314-328
Kizaki, M.; Koeffler, H.P. 1992: Differentiation-inducing agents in the treatment of myelodysplastic syndromes Seminars in Oncology 19(1): 95-105
Yoshida, Y. 1991: Interferon gamma induces differentiation of cells from patients with myelodysplastic syndromes in vitro and in vivo Leukemia 5(9): 796-798
Gattei, V.; Aldinucci, D.; Petti, M.C.; Da Ponte, A.; Zagonel, V.; Pinto, A. 1993: In vitro and in vivo effects of 5-aza-2'-deoxycytidine (Decitabine) on clonogenic cells from acute myeloid leukemia patients Leukemia 7(Suppl 1): 42-48
Schwartsmann, G.; Fernandes, M.S.; Schaan, M.D.; Moschen, M.; Gerhardt, L.M.; Di Leone, L.; Loitzembauer, B.; Kalakun, L. 1997: Decitabine (5-Aza-2'-deoxycytidine; DAC) plus daunorubicin as a first line treatment in patients with acute myeloid leukemia: preliminary observations Leukemia 11(Suppl 1): S28-S31
Tanaka, T.; Tanaka, K.; Ogawa, S.; Kurokawa, M.; Mitani, K.; Nishida, J.; Shibata, Y.; Yazaki, Y.; Hirai, H. 1995: An acute myeloid leukemia gene, AML1, regulates hemopoietic myeloid cell differentiation and transcriptional activation antagonistically by two alternative spliced forms EMBO Journal 14(2): 341-350
Fenaux, P.; Collyn d'Hooghe, M.; Jonveaux, P.; Lai, J.L.; Bauters, F.; Loucheux, M.H.; Kerckaert, J.P. 1990: Rearrangement and expression of the p53 gene in myelodysplastic syndrome and acute myeloid leukemia Nouvelle Revue Francaise d'Hematologie 32(5): 341-344
Xie, J.; Briggs, J.A.; Morris, S.W.; Olson, M.O.; Kinney, M.C.; Briggs, R.C. 1997: MNDA binds NPM/B23 and the NPM-MLF1 chimera generated by the t(3;5) associated with myelodysplastic syndrome and acute myeloid leukemia Experimental Hematology 25(11): 1111-1117
Stegmann, A.P.; Honders, M.W.; Kester, M.G.; Landegent, J.E.; Willemze, R. 1993: Role of deoxycytidine kinase in an in vitro model for AraC- and DAC-resistance: substrate-enzyme interactions with deoxycytidine, 1-beta-D-arabinofuranosylcytosine and 5-aza-2'-deoxycytidine Leukemia 7(7): 1005-1011
Cheson, B.D.; Simon, R. 1987: Low-dose ara-C in acute nonlymphocytic leukemia and myelodysplastic syndromes: a review of 20 years' experience Seminars in Oncology 14(2 Suppl 1: 126-133
Kolarz, G.; Pietschmann, H. 1972: Familial myeloid leukaemias Wiener Klinische Wochenschrift 84(49): 790-792
Nasu, H.; Hibi, N.; Ohyashiki, J.H.; Hara, A.; Kubono, K.; Tsukada, Y.; Ando, K.; Iwama, H.; Hayashi, S.; Yahata, N.; Toyama, K.; Ohyashiki, K. 1998: Serum soluble CD44 levels for monitoring disease states in acute leukemia and myelodysplastic syndromes International Journal of Oncology 13(3): 525-530